ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts.

[1]  R. Busse,et al.  Ramiprilat Enhances Endothelial Autacoid Formation by Inhibiting Breakdown of Endothelium‐Derived Bradykinin , 1991, Hypertension.

[2]  P. Munch,et al.  Bradykinin increases myocardial contractility: relation to the Gregg phenomenon. , 1991, The American journal of physiology.

[3]  R. Tallarida,et al.  Pharmacological evidence that captopril possesses an endothelium-mediated component of vasodilation: effect of sulfhydryl groups on endothelium-derived relaxing factor. , 1991, The Journal of pharmacology and experimental therapeutics.

[4]  W. König,et al.  Hoe 140 a new potent and long acting bradykinin‐antagonist: in vivo studies , 1991, British journal of pharmacology.

[5]  Jon M. Fukuto,et al.  Shear Stress‐Induced Release of Nitric Oxide From Endothelial Cells Grown on Beads , 1991, Hypertension.

[6]  I. Morita,et al.  Synthesis and release of acetylcholine by cultured bovine arterial endothelial cells , 1990, Neuroscience Letters.

[7]  V. Miller.  Does antihypertensive therapy improve the function of the vascular endothelium? , 1990, Hypertension.

[8]  G. Burnstock,et al.  Endothelial cells cultured from human umbilical vein release ATP, substance P and acetylcholine in response to increased flow , 1990, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[9]  W. Linz,et al.  Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. , 1990, European journal of pharmacology.

[10]  B. Lipworth,et al.  Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade. , 1989, British journal of clinical pharmacology.

[11]  O. Carretero,et al.  Kinin Antagonist Reverses Converting Enzyme Inhibitor‐Stimulated Vascular Prostaglandin I2 Synthesis , 1989, Hypertension.

[12]  J. McMurray,et al.  Captopril: a free radical scavenger. , 1989, British journal of clinical pharmacology.

[13]  J. Vane,et al.  Effect of Captopril on the bradykinin‐induced release of prostacyclin from guinea‐pig lungs and bovine aortic endothelial cells , 1988, British journal of pharmacology.

[14]  R. Busse,et al.  Differential role of extra‐ and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells , 1988, British journal of pharmacology.

[15]  P. D. de Groot,et al.  High-molecular weight kininogen is present in cultured human endothelial cells: localization, isolation, and characterization. , 1988, Blood.

[16]  M. Bernier,et al.  Reperfusion-induced arrhythmias: mechanisms of protection by glucose and mannitol. , 1988, The American journal of physiology.

[17]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[18]  V. Dzau,et al.  Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. , 1987, Circulation research.

[19]  T. Metsä-Ketelä,et al.  The effects of cyclic AMP and cyclic GMP on redox state and energy state in hypoxic rat atria. , 1984, Life sciences.

[20]  J. Eckel,et al.  Influence of bradykinin on glucose uptake and metabolism studied in isolated cardiac myocytes and isolated perfused rat hearts. , 1983, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[21]  L. Opie,et al.  Effects of Substrates on Tissue Metabolic Changes in the Isolated Rat Heart during Underperfusion and on Release of Lactate Dehydrogenase and Arrhythmias during Reperfusion , 1978, Circulation research.

[22]  S. Furukawa,et al.  Changes in components of kinin system and hemodynamics in acute myocardial infarction. , 1978, American heart journal.

[23]  S. Furukawa,et al.  Changes in hemodynamics and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. , 1977, Japanese heart journal.

[24]  W. Linz,et al.  Local Inhibition of Bradykinin Degradation in Ischemic Hearts , 1990, Journal of cardiovascular pharmacology.

[25]  K. Shimamoto,et al.  Role of Kallikrein‐Kinin System in the Hypotensive Mechanisms of Converting Enzyme Inhibitors in Essential Hypertension , 1989, Journal of cardiovascular pharmacology.

[26]  P. Vanhoutte,et al.  Why are converting enzyme inhibitors vasodilators? , 1989, British journal of clinical pharmacology.

[27]  J. Parratt,et al.  Eicosanoids and susceptibility to ventricular arrhythmias during myocardial ischaemia and reperfusion. , 1987, Journal of molecular and cellular cardiology.

[28]  W. Linz,et al.  Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. , 1986, Journal of cardiovascular pharmacology.